KBKeith Burkhart

Keith Burkhart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keith Burkhart has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey Brent

    University of Colorado School of Medicine , Aurora , Colorado, USA , ucdenver.edu

    4 shared publications
  • Kim Aldy

    Baylor University Medical Center , Dallas , Texas, USA , baylor.edu

    4 shared publications
  • Paul Wax

    American College of Medical Toxicology, Phoenix, AZ, United States

    4 shared publications
  • Albert Dahan

    Centre for Human Drug Research, 2333CL Leiden, The Netherlands

    2 shared publications
  • David G. Strauss

    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

    2 shared publications
  • Jeffry Florian

    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA

    2 shared publications

Latest Publications

  • Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial

    by Jeffry Florian, Dro Keshishi, Victoria Gershuny, Pablo Salcedo, Rutger van der Schrier, Keith Burkhart, Aanchal Shah, Rebecca Racz, Vikram Patel, Ryan DePalma, et al.

    Background: Opioid-induced respiratory depression remains a critical public safety concern. Previous clinical findings demonstrated decreased hypercapnic ventilation after 5 days when paroxetine, a selective serotonin reuptake inhibitor (SSRI), was administered alone or with oxycodone. However, uncertainty remained whether chronic use of SSRIs could cause similar respiratory effects. This study investigated whether chronic use of paroxetine and another SSRI, escitalopram, led to a similar decrease in ventilatory response to hypercapnia. Methods: In this randomized, double-blind, three-period crossover trial, healthy participants were administered one of the following: 40 mg paroxetine from days 1 to 6 and 60 mg from days 7 to 21, 20 mg escitalopram from days 1 to 6 and 30 mg from days 7 to 21, and placebo from days 1 to 21. A dose of 10 mg oxycodone was coadministered on days 6, 12, and 21. Hyperoxic–hypercapnic ventilation was measured using Duffin’s rebreathing. Results: Of the 27 participants, 22 (81%) completed the trial. Paroxetine and escitalopram both significantly decreased hyperoxic–hypercapnic ventilation when coadministered with oxycodone compared to oxycodone alone on day 21 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −3.1; P < 0.001; escitalopram mean difference, −5.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.001) and when administered alone compared to placebo on day 20 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.003; escitalopram mean difference, −6.9 l/min; one-sided 97.5% CI, −∞ to −2.5; P = 0.002). Conclusions: Both paroxetine and escitalopram, alone and coadministered with oxycodone, decrease hypercapnic ventilation after 21 days, suggesting that SSRIs may have a class effect on hypercapnic ventilation that persists with chronic use.

  • Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdose

    by Alyssa M. Falise, Amanda Sutphin, Rachel Culbreth, Kim Aldy, Keith Burkhart, Jeffrey Brent, Sharan L. Campleman, Hannah Day, Aprielle Wills, Alex Krotulski, et al.


  • Open Access

    Effect of midazolam co-administered with oxycodone on ventilation: a randomised clinical trial in healthy volunteers

    by Victoria Gershuny, Jeffry Florian, Rutger van der Schrier, Michael C. Davis, Pablo Salcedo, Celine Wang, Keith Burkhart, Kristin Prentice, Aanchal Shah, Rebecca Racz, et al.


  • Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry

    by Jonathan Schimmel, Lindsey Claire Epperson, Kim Aldy, Paul Wax, Jeffrey Brent, Jennie Buchanan, Michael Levine, Keith Burkhart, the Toxicology Investigators Consortium FACT Study Group

    Background Remdesivir is an antiviral approved by the US Food and Drug Administration (FDA) for treatment of coronavirus disease 2019 (COVID-19), and aminotransferase elevation is commonly reported. Thresholds to be considered for discontinuation due to alanine aminotransferase (ALT) elevation differ between the FDA and European Medicines Agency (EMA). The primary objective was to describe aminotransferase thresholds being used in real-world practice for discontinuation of remdesivir in patients with COVID-19, and compare them with labeled recommendations. Methods This study used a descriptive design based on an ongoing national registry of adverse events, the FDA ACMT COVID-19 ToxIC (FACT) pharmacovigilance project, with 17 participating health systems in the USA. Cases were identified retrospectively for an 18-month period (23 November 2020–18 May 2022). Classification of discontinuation as premature and due to aminotransferases was based on chart documentation by the treating team. Results Of 1026 cases in the FACT registry, 116 cases were included with supplemental data forms completed for aminotransferase elevation with remdesivir, defined a priori for inclusion as ALT doubling or increasing by ≥ 50 U/L. ALT was elevated prior to remdesivir in 47% and increased above baseline during dosing by a median of 92 U/L [interquartile range (IQR) 51–164, max 8350]. Remdesivir was discontinued early in 37 (31.9%) patients due to elevated aminotransferases. The ALT threshold for premature discontinuation was median 200 U/L (IQR 145–396, range 92–5743). Among patients with premature discontinuation of remdesivir for aminotransferase elevation, only 21.6% met FDA criteria to consider discontinuation, and 40.5% met prior EMA criteria to consider discontinuation. Conclusion In this descriptive study of real-world practice in the USA, clinicians are overall making more conservative treatment decisions than are recommended for consideration in approved drug labeling of discontinuation, with wide variation in the aminotransferase thresholds being used.


  • Methanol poisonings from contaminated hand sanitizers identified by the United States Food and Drug Administration

    by Karen Konkel, Keith Burkhart, Carmen Cheng, Regina Lee, Theresa Michele, Evelyn Mentari, Ida-Lina Diak, Lynda Mcculley


  • Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics

    by Mark Simon, Jennie Buchanan, Jonathan Schimmel, Jeffrey Brent, Keith Burkhart, Paul Wax, Natalie Taylor, Kim Aldy, On behalf of the Toxicology Investigators Consortium FACT Study Group

    Background Pregnant patients are at high risk of maternal and fetal complications from Coronavirus Disease 2019 (COVID-19) infections. The COVID-19 pandemic prompted a surge in the development and repurposing of therapies for the SARS-CoV-2 virus. Evidence is sparse on the efficacy and safety of these therapies in pregnant patients. Our objective was to describe adverse events (AEs) to COVID-19 therapeutics in pregnant patients. Methods This was a case series of AEs reported to the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Project between November 23, 2020, and June 28, 2022. FACT is an ongoing toxicosurveillance project at 17 sites to proactively identify and report AEs associated with COVID-19 therapeutics. Abstracted information includes demographics, case narratives, exposure details, clinical information, pregnancy details, treatments, and outcomes. Results Forty-six COVID-19-positive pregnant patients who developed AEs following COVID-19 therapeutics were reported to the FACT Pharmacovigilance Project over 19 months. The most reported medications were remdesivir in 22 patients (47.8%) and casirivimab/imdevimab in 8 patients (17.4%). Four patients (8.7%) had life-threatening clinical manifestation, and 16 patients (34.8%) required intervention to prevent permanent damage. The most common maternal and fetal events were elevated serum alanine aminotransferase (26.1%) and non-reassuring fetal heart patterns (20.0%), respectively. Conclusions This case series reports AEs of elevated serum alanine aminotransferase, maternal bradycardia, maternal hypothermia, non-reassuring fetal heart patterns, and emergent or unplanned cesarean sections following administration of several COVID-19 therapeutics. This study was not designed to definitely identify causation, and further study is needed to evaluate the causal role of these therapeutics in AEs affecting pregnant COVID-19 patients.


  • Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project

    by Rita Farah, Ziad Kazzi, Jeffrey Brent, Keith Burkhart, Paul Wax, Kim Aldy, On behalf of the Toxicology Investigators Consortium FACT Study Group

    In August 2021, the Centers for Disease Control and Prevention (CDC) released a health alert following the rapid increase in ivermectin prescriptions and reports of severe illness associated with u...